Toggle navigation
Home
Search
Services
Blog
Contact
About
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara
Biocryst Pharmaceuticals, Inc., Birmingham, AL, United States
Search 146 grants from Y Babu
Search grants from Biocryst Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Building Libraries with Chemical Diversity for Screening
Florida Node Alliance of the Drug Abuse Clinic Trials Network
SMART: A Social and Mobile Weight Control Program for Young Adults
Role of the Erythropoietin Receptor in Erythropoiesis
Minority Undergraduate Marine Research Program
Recently added grants:
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus
Physiological roles of schistosome TRP ion channels with atypical pharmacology
The role of VTA neurotransmitter co-release in health and disease
IRF4+ respiratory dendritic cells in type 2 inflammatory responses
Role of Stx11 and STXBP2 in lytic granule exocytosis in health and disease
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AR041095-03
Application #
2080467
Study Section
Special Emphasis Panel (ZRG7-SSS-6 (06))
Project Start
1994-02-16
Project End
1996-02-15
Budget Start
1995-04-05
Budget End
1996-02-15
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Biocryst Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
Related projects
NIH 1995
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
NIH 1994
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant